The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Professor John Wilding leads clinical research into Obesity, Diabetes and Endocrinology at the University of Liverpool, where he has worked since 1996, after training in Southampton and London. His clinical interests focus on caring for people with diabetes and obesity and he leads specialist services for obesity at Aintree University Hospital, which has been designated a Centre for Obesity Management by the European Association for the Study of Obesity.
Professor Wilding’s research team focusses on developing and evaluating treatments for obesity and diabetes. He has published over 350 papers and chapters and review articles, including clinical trials in diabetes and obesity and studies of adipocyte biology and metabolism.
Professor Wilding chairs the National Clinical Research Network Metabolic and Endocrine Speciality Group. He is Past-Chair of the UK Association for the Study of Obesity, a member of the Royal College of Physicians Advisory Group on Nutrition, Weight and Health, and President of the World Obesity Federation.